Related Experiment Videos
Brain metastases: still an 'orphan' disease?
1Department of Clinical Neuro-Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 0100, Houston, TX 77030, USA. mrgilbert@mdanderson.org
Current Oncology Reports
|October 12, 2001
Summary
Brain metastases from cancer indicate a poor prognosis, often excluding patients from chemotherapy trials. However, new strategies in neurosurgery, radiotherapy, and targeted chemotherapy show promise for improved management.
Area of Science:
- Neuro-oncology
- Translational Cancer Research
- Clinical Trial Design
Background:
- Brain metastases from systemic cancer are linked to poor patient prognosis.
- Historically, chemotherapy clinical trials have largely excluded patients with metastatic disease, limiting research.
- Previous clinical and basic research in this area has been limited.
Purpose of the Study:
- To review recent advancements in the management of brain metastases.
- To highlight emerging treatment strategies and their potential impact.
- To emphasize the need for focused investigation into chemotherapy's role.
Main Methods:
- Review of recent developments in clinical trial design, including recursive partitioning analysis.
- Integration of new treatment strategies in neurosurgery and radiotherapy.
- Analysis of recent advances in understanding the biology of brain metastases.
Main Results:
- Recent developments indicate a shift in the approach to managing brain metastases.
- New treatment strategies in neurosurgery and radiotherapy are complementing clinical trial design.
- Advances in understanding metastasis biology are paving the way for next-generation therapies.
Conclusions:
- The management of brain metastases is evolving with improved clinical trial designs and treatment modalities.
- Targeted therapies based on the specific biology of brain metastases are anticipated.
- Further focused research is crucial to optimize chemotherapy's role in treating brain metastases.